| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.002 | 0.9 |